EARLY BREAST CANCER

This study looks at whether a genetic test (Prosigna®) can help decide if younger women with early, hormone-sensitive breast cancer need chemotherapy. About 3380 premenopausal women will either get standard treatment (chemo plus hormone therapy) or a treatment plan based on the t…

This study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery to women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this treatment can eliminate all cancer cells in the breast and lymph nodes by the time…

This phase 3 trial is testing a daily pill called giredestrant in 300 people with early-stage, hormone-sensitive breast cancer who had side effects from standard aromatase inhibitors. The study will track how well patients stick with the treatment, any side effects, and changes i…

This study will analyze medical records from 100,000 people in Korea who had early-stage hormone receptor-positive, HER2-negative breast cancer and received surgery followed by other treatments. The goal is to see how often the cancer comes back and what factors might affect that…

This study looks at 2,000 women with HER2-positive early breast cancer who still had cancer after initial treatment. Researchers compare two different follow-up drug combinations to see which one helps prevent the cancer from coming back. The goal is to find the best approach for…

This study will follow 81 people with early-stage, hormone-positive breast cancer who are at high risk of the cancer coming back. Researchers want to see how often patients take their prescribed CDK4/6 inhibitor pills (abemaciclib or ribociclib) alongside standard hormone therapy…